THALES
10.4.2024 11:40:33 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced a collaboration leveraging its CipherTrust Data Security Platform (CDSP) to support End-To-End Data Protection (E2EDP) on Google Cloud, using Confidential Computing (CC) from Google Cloud and trusted cloud independent attestation provided by Intel Trust Authority (ITA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410848317/en/
©Thales
The effort is a step forward in data security, giving enterprises additional controls to protect their data at rest, in transit, and in use.
“As more enterprises migrate their data and workloads to the cloud, there is an increasing demand to safeguard the privacy and integrity of the data, especially those sensitive workloads that include intellectual property, AI models and valuable personal information. This collaboration enables enterprises to protect and control their data at rest, in transit and in use with fully verifiable attestation. Our close collaboration with Google Cloud and Intel increases our customers' trust in their cloud migration,” said Todd Moore, Vice President of Data Security Products at Thales.
A majority of the 2023 Thales Cloud Security Study respondents reported having a significant amount of sensitive data stored and in use in the cloud. Consequently, safeguarding sensitive data and associated workloads when stored or in use, is an increasing priority, especially for highly regulated industries such as financial services and healthcare. Thales's collaboration with Intel and Google Cloud provides certifiable controls for enterprises to fully protect their data end-to-end.
Purnam Sheth, Vice President and General Manager: Trust and Security Products, SATG at Intel: “Creating this groundbreaking, seamless data security platform in Google Cloud meets customers’ complex requirements for data protection, controlled access and security, and adherence to compliance for data at rest, in transit and in use. Foundational Intel® Trust Domain Extensions Confidential Compute and Intel® Trust Authority gives enterprises assurance of the integrity of their workloads and guards at all stages of data management. This valuable collaboration between Thales, Google Cloud and Intel makes this possible.”
This security platform is based on the principle of separation of duties, where the customer remains in control of the encryption keys and their location. This approach enhances trust by holding each stakeholder responsible for their respective roles and reduces the ability for a malicious actor to access code and data at rest, in transit and while being executed.
Customers can migrate existing workloads with sensitive data or create new workloads needing zero trust, confidential computing and Confidential AI to this security platform in Google Cloud to broaden data security, attestation and set the right authorizations. With end-to-end data protection, multiple parties can securely collaborate on various use cases, such as Confidential AI datasets and models as needed while preserving privacy, confidentiality, and compliance with privacy regulations.
The Thales CipherTrust Data Security Platform uses Intel Trust Authority as a zero-trust, independent attestation service for advanced security and scalable confidential computing. Consistent attestation to Trusted Execution Environments (TEE) that are based on Intel Trust Domain Extensions. This single, consistent attestation process provides assurance to any relying party that the TEE and any data and workloads running within it have not been compromised.
Brian Roddy, VP, Product Management, Google Cloud: “Google Cloud is committed to providing our customers secure, private and reliable environments for their workloads, and our Confidential Computing portfolio plays a critical role in this effort. Offering our customers solutions like Thales’ encryption key management expertise, combined with Intel’s Trust Authority attestation, enables the choice of even stronger privacy controls.”
The collaboration comes as Thales is recognized for its achievements in the Google Cloud ecosystem. For the second year in a row, Thales has received the 2024 Google Cloud Technology Partner of the Year Award for Security - Data Protection.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Artificial Intelligence, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410848317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
